There is a critical gap in research in terms of understanding the profile of those seeking the glucagon-like peptide-1 receptor agonists (GLP1), and the consequences when ceasing use. This is a crucial area of research given the potential use of these medications among vulnerable populations such as those experiencing eating disorders and body image dissatisfaction. The aim of this research is to examine the experience of key stakeholders and consumers regarding the use of GLP1s and their relationship to body image distress and disordered eating to contribute to the development of lived-experienced, clinician endorsed treatment and assessment guidelines.

​

Chief Investigator: Dr Kathleen de Boer

Associated Investigators: Dr Inge Gnatt, Dr Courtney McLean, Dr Brooke Healey, Ms Jo Money & Ms Evie Gardiner.